Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Navoximod |
| Trade Name | |
| Synonyms | NLG919|RG6078|GDC-0919|RO7077339-001 |
| Drug Descriptions |
Navoximod (GDC-0919) inhibits indoleamine 2,3-dioxygenase 1 (IDO1), which decreases production of kynurenine from tryptophan, potentially resulting in reduced T-cell suppression and increased antitumor immune response (PMID: 31124055, PMID: 29247038). |
| DrugClasses | IDO1 Inhibitor 13 |
| CAS Registry Number | 1402837-78-8 |
| NCIT ID | C113793 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Navoximod | Atezolizumab Navoximod | 0 | 0 |
| Navoximod | Navoximod | 0 | 2 |
| Navoximod + NLG802 | NLG802 Navoximod | 0 | 1 |